Johnson & Johnson (JNJ) Operating Margin (2009 - 2026)
Johnson & Johnson recorded quarterly Operating Margin of 26.44% in Q1 2026, down 67.62% quarter-over-quarter from 81.68% in Q4 2025, and down 179.0% year-over-year from 33.47% in Q1 2025.
Johnson & Johnson's Operating Margin history runs 18 years deep, the most recent figure standing at 26.44% for Q1 2026.
- In Q1 2026, Operating Margin fell 179.0% year-over-year to 26.44%; the TTM figure through Mar 2026 stood at 41.62% (up 1779.0% YoY), while the FY2025 annual figure was 42.39%, up 1873.0% from the prior year.
- Operating Margin came in at 26.44% for Q1 2026 at Johnson & Johnson, down from 81.68% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 88.12% in Q4 2023 to a low of 15.98% in Q4 2024.
- A 5-year average of 33.75% and a median of 27.36% in 2023 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin sank 7214 bps in 2024 and jumped 6570 bps in 2025, its largest moves.
- Johnson & Johnson's Operating Margin stood at 26.5% in 2022, then jumped by 233 bps to 88.12% in 2023, then slumped by 82 bps to 15.98% in 2024, then soared by 411 bps to 81.68% in 2025, then tumbled by 68 bps to 26.44% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 26.44%, 81.68%, and 29.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.58% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 26.44% |
| Dec 28, 2025 | 81.68% |
| Sep 28, 2025 | 29.31% |
| Jun 29, 2025 | 27.99% |
| Mar 30, 2025 | 28.24% |
| Dec 29, 2024 | 15.98% |
| Sep 29, 2024 | 22.42% |
| Jun 30, 2024 | 28.82% |
| Mar 31, 2024 | 27.63% |
| Dec 31, 2023 | 88.12% |
| Oct 1, 2023 | 26.88% |
| Jul 2, 2023 | 27.01% |
| Apr 2, 2023 | 27.36% |
| Jan 1, 2023 | 48.19% |
| Oct 2, 2022 | 26.50% |
| Jul 3, 2022 | 19.19% |
| Apr 3, 2022 | 21.94% |
| Oct 3, 2021 | 28.31% |
| Jul 4, 2021 | 26.60% |
| Apr 4, 2021 | 29.55% |
| Jan 3, 2021 | 36.24% |
| Sep 27, 2020 | 27.37% |
| Jun 28, 2020 | 21.79% |
| Mar 29, 2020 | 27.97% |
| Dec 29, 2019 | 19.72% |
| Sep 29, 2019 | 28.08% |
| Jun 30, 2019 | 26.03% |
| Mar 31, 2019 | 26.44% |
| Dec 30, 2018 | 19.57% |
| Sep 30, 2018 | 27.12% |
| Jul 1, 2018 | 25.66% |
| Apr 1, 2018 | 28.09% |
| Dec 31, 2017 | 14.68% |
| Oct 1, 2017 | 23.05% |
| Jul 2, 2017 | 28.03% |
| Apr 2, 2017 | 30.19% |
| Jan 1, 2017 | 25.17% |
| Oct 2, 2016 | 29.60% |
| Jul 3, 2016 | 30.11% |
| Apr 3, 2016 | 30.40% |
| Jan 3, 2016 | 64.84% |
| Sep 27, 2015 | 27.15% |
| Jun 28, 2015 | 27.64% |
| Mar 29, 2015 | 30.77% |
| Dec 28, 2014 | 21.61% |
| Sep 28, 2014 | 30.20% |
| Jun 29, 2014 | 30.62% |
| Mar 30, 2014 | 31.17% |
| Dec 29, 2013 | 22.18% |
| Sep 29, 2013 | 27.74% |
| Jun 30, 2013 | 28.34% |
| Mar 31, 2013 | 28.24% |
| Dec 30, 2012 | 23.65% |
| Sep 30, 2012 | 25.24% |
| Jul 1, 2012 | 27.93% |
| Apr 1, 2012 | 28.28% |
| Jan 1, 2012 | 9.26% |
| Oct 2, 2011 | 24.49% |
| Jul 3, 2011 | 22.53% |
| Apr 3, 2011 | 28.45% |
| Jan 2, 2011 | 67.78% |
| Oct 3, 2010 | 26.85% |
| Jul 4, 2010 | 28.02% |
| Apr 4, 2010 | 30.50% |
| Jan 3, 2010 | 13.27% |
| Sep 27, 2009 | 28.27% |
| Jun 28, 2009 | 28.57% |
| Mar 29, 2009 | 30.94% |